Enoximone

Drug Profile

Enoximone

Alternative Names: fenoximone; MDL 17043; Perfan; Perfan®IV

Latest Information Update: 21 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Cardiotonics; Imidazoles; Small molecules; Vasodilators
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 18 Nov 2006 Myogen has been acquired by Gilead Sciences
  • 07 Feb 2006 Myogen Inc. has sold Myogen GmbH and the sublicense of its rights to intravenous enoximone in markets outside North America, to Wulfing Holding GmbH
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top